Commission accepts commitments by Sanofi to address possible anticompetitive disparagement of competing flu vaccine for vulnerable patients
What happened
On 14 October 2026, the European Commission accepted commitments offered by Sanofi, making them legally binding under EU antitrust rules. These commitments address the Commission's preliminary competition concerns that Sanofi allegedly disparaged Fluad, a competing enhanced flu vaccine for vulnerable patients. This alleged disparagement campaign occurred in Germany and France.
Why it matters
This action aims to ensure fair competition in the market for enhanced flu vaccines for vulnerable patients. It addresses concerns that Sanofi's alleged actions might have unfairly disadvantaged a competitor's product, potentially limiting patient choice.
Who it affects
- ›Sanofi, a pharmaceutical company.
- ›Manufacturers of enhanced flu vaccines, like Fluad.
- ›Vulnerable patients needing enhanced flu vaccines.
- ›Healthcare markets in Germany and France.
The receipts are official. The summary is ours.
Read on European Commission ↗Summaries are generated from the official text and may simplify or omit nuance. The official document is the source of truth.